

Colin Proksel (034133)
OSBORN MALEDON, P.A.
2929 North Central Avenue, 21st Floor
Phoenix, Arizona 85012-2793
State Bar No. 034133
Telephone: (602) 640-9000
Facsimile: (602) 640-9050
Email: cproksel@omlaw.com

Attorney for Plaintiffs

Additional counsel listed on following page

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF ARIZONA
TUCSON DIVISION**

Jane Doe, by her next friend and parents
Helen Doe and James Doe; and Megan Roe,
by her next friend and parents, Kate Roe and
Robert Roe,

Plaintiffs,

v.

Thomas C. Horne in his official capacity as
State Superintendent of Public Instruction;
Laura Toenjes, in her official capacity as
Superintendent of the Kyrene School
District; Kyrene School District; The
Gregory School; and Arizona Interscholastic
Association Inc.,

Defendants.

Case No. _____

**DECLARATION OF DR. DANIEL
SHUMER, M.D., MPH, IN SUPPORT OF
PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION AND
PLAINTIFFS' MOTION TO PROCEED
UNDER A PSEUDONYM**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 Jyotin Hamid*
2 Justin R. Rassi*
3 Amy C. Zimmerman*
4 DEBEVOISE & PLIMPTON LLP
5 66 Hudson Boulevard
6 New York, New York 10001
7 Telephone: (212) 909-6000
8 Facsimile: (212) 909-6836
9 Email: jhamid@debevoise.com
10 Email: jrassi@debevoise.com
11 Email: azimmerman@debevoise.com

12 Amy Whelan*
13 Rachel Berg*
14 NATIONAL CENTER FOR LESBIAN RIGHTS
15 870 Market Street, Suite 370
16 San Francisco, California 94102
17 Telephone: (415) 343-7679
18 Facsimile: (415) 392-8442
19 Email: awhelan@nclrights.org
20 Email: rberg@nclrights.org

21 **Pro hac vice application forthcoming*

22
23
24
25
26
27
28

1 I, Daniel Evan Shumer, M.D., declare as follows:

2 1. I submit this expert declaration based upon my personal knowledge.

3 2. If called to testify in this matter, I would testify truthfully based on my
4 expert opinion.

5 **Qualifications and Experience**

6 3. I am a Pediatric Endocrinologist and Medical Director of the
7 Comprehensive Gender Services Program at Michigan Medicine, University of
8 Michigan. I also serve as the Clinical Director of Child and Adolescent Gender Services
9 at C.S. Mott Children's Hospital, and as an Assistant Professor of Medicine at the
10 University of Michigan, where the major focus of my clinical and research work pertains
11 to transgender adolescents. A true and correct copy of my curriculum vitae is attached
12 hereto as **Exhibit A**.

13 4. I received my medical degree from Northwestern University in 2008. After
14 completing a residency in pediatrics at Vermont Children's Hospital, Fletcher Allen
15 Health Care, University of Vermont, I began a clinical fellowship in pediatric
16 endocrinology at Harvard University's Boston Children's Hospital. During that clinical
17 fellowship, I completed a Master of Public Health from Harvard University's T.H. Chan
18 School of Public Health. I finished both the fellowship and my MPH degree in 2015.

19 5. As a fellow at Harvard, I was mentored by Dr. Norman Spack, a pioneer in
20 transgender medicine who established the Gender Management Services Clinic (GeMS),
21 the first major program in the U.S. to focus on gender-diverse and transgender
22 adolescents. GeMS is located at Boston Children's Hospital. Working at GeMS, I became
23 a clinical expert in the field of transgender medicine within pediatric endocrinology and
24 began conducting research on gender identity and the evaluation and management of
25 transgender children and adolescents.

26 6. Based on my work at GeMS, I was recruited to establish a similar program
27 focusing on gender-diverse and transgender children and adolescents at the C.S. Mott
28

1 Children’s Hospital. In October 2015, I founded the hospital’s Child and Adolescent
2 Gender Services Clinic.

3 7. The Child and Adolescent Gender Services Clinic has treated over 600
4 patients since its founding. I have personally evaluated and treated over 400 patients for
5 gender dysphoria. As the Clinical Director, I oversee the clinical practice, which includes
6 four other physicians, two clinical social workers, and nursing and administrative staff. I
7 also actively conduct research related to transgender medicine and mental health
8 concerns specific to transgender youth.

9 8. In addition to my work with transgender children and adolescents, I also
10 treat children and adolescents with differences of sex development (“DSD”), commonly
11 referred to as intersex conditions. I participate in the DSD Clinic’s monthly meetings and
12 approximately 5% of my patients are children and adolescents with DSDs.

13 9. My academic duties as an assistant professor include teaching lectures
14 entitled “Puberty,” “Transgender Medicine,” and “Pediatric Growth and Development.”
15 I am also the Director of the Transgender Medicine elective for the University of
16 Michigan Medical School.

17 10. My recent publications include *Health Disparities Facing Transgender and*
18 *Gender Nonconforming Youth Are Not Inevitable*, *Pediatrics*, 141(3), 1–2 (2018);
19 *Psychological Profile of the First Sample of Transgender Youth Presenting for Medical*
20 *Intervention in a U.S. Pediatric Gender Center*, *Psych. Sexual Orientation & Gender*
21 *Diversity*, 4(3), 374–82 (2017); *The Effect of Lesbian, Gay, Bisexual, and Transgender-*
22 *Related Legislation on Children*, *J. Pediatrics*, 178(5-6.e1), 5–7 (2016); *Advances in the*
23 *Care of Transgender Children and Adolescents*, *Advances Pediatrics*, 63(1), 79-102
24 (2016); *The Role of Assent in the Treatment of Transgender Adolescents*, *Int’l J.*
25 *Transgenderism*, 16(2), 97-102 (2015); and *Serving Transgender Youth: Challenges,*
26 *Dilemmas, and Clinical Examples*, *Professional Psychology: Research and Practice*,
27 46(1), 37–45 (2015). I have also co-authored chapters of textbooks, including “Medical
28

1 Treatment of the Adolescent Transgender Patient” in *Gender Affirmation: Medical and*
2 *Surgical Perspectives* (Christopher J. Salgado et al. eds., 2016). A listing of my
3 publications is included in my curriculum vitae in **Exhibit A**.

4 11. I have been invited to speak at numerous hospitals, clinics, and conferences
5 on topics related to clinical care and standards for treating transgender children and
6 youth. For example, in December 2017 I spoke at the Nursing Unit (12-West) Annual
7 Educational Retreat in Michigan on the topic of “Gender Identity at the Children’s
8 Hospital,” and in October 2017, I planned, hosted, and spoke at a conference in Michigan
9 entitled “Transgender and Gender Non-Conforming Youth: Best Practices for Mental
10 Health Clinicians, Educators, & School Staff.”

11 12. In October 2019, I was invited by the Michigan Organization on
12 Adolescent Sexual Health to speak to community groups across Southeast Michigan on
13 the topic of “Gender Identity in Adolescents—Supporting Transgender Youth.” A listing
14 of my lectures is included in my curriculum vitae in **Exhibit A**.

15 13. I belong to a number of professional organizations and associations relating
16 to (i) the health and well-being of children and adolescents, including those who are
17 transgender; and (ii) appropriate medical treatments for transgender individuals. For
18 example, I am currently a member of the Pediatric Endocrine Society where I serve on
19 the Gender Identity Special Interest Group’s Education Committee, and the World
20 Professional Association for Transgender Health (“WPATH”), an international
21 multidisciplinary professional association to promote evidence-based care, education,
22 research, advocacy, public policy, and respect in transgender health. Both organizations
23 are central in the development of the standards of care for the treatment of gender
24 dysphoria. A complete list of my involvement in various professional associations is
25 located in my curriculum vitae in **Exhibit A**.

26 14. In preparing this declaration, I reviewed the text of Senate Bill 1165 (“SB
27 1165”) at issue in this matter. I also relied on my scientific education and training, my
28

1 research experience, and my knowledge of the scientific literature in the pertinent fields.
2 The materials I have relied upon in preparing this declaration are the same types of
3 materials that experts in my field of study regularly rely upon when forming opinions on
4 these subjects. I may wish to supplement these opinions or the bases for them as a result
5 of new scientific research or publications or in response to statements and issues that may
6 arise in my area of expertise.

7 15. I have not met or spoken with the Plaintiffs or their parents for purposes of
8 this declaration. My opinions are based solely on the information that I have been
9 provided by Plaintiffs' attorneys as well as my extensive background and experience
10 treating transgender patients.

11 16. In the past four years, I have been retained as an expert and provided
12 testimony on behalf of transgender plaintiffs in the following cases: *Dekker v. Weida*, No.
13 4:22-cv-00325-RH-MAF (N.D. Fla.); *Boe v. Marshall*, No. 2:22-cv-00184-LCB-CWB
14 (M.D. Ala.); *Roe v. Utah High Sch. Activities Ass'n*, No. 220903262 (3d Jud. Dist. in and
15 for Salt Lake County, Utah); *Menefee v. City of Huntsville Bd. of Educ.*, No. 5:18-cv-
16 01481-LCB (N.D. Ala.); *Flack v. Wis. Dep't of Health Servs.*, No. 3:18-cv-00309-wmc
17 (W.D. Wis.); *Whitaker v. Kenosha Unified Sch. Dist. No. 1 Bd. of Educ.*, No. 2:16-cv-
18 00943-PP (E.D. Wis.). I also provided expert witness testimony on behalf of a parent in a
19 custody dispute involving a transgender child in the following case: *In the Interest of*
20 *Younger*, No. DF-15-09887 (Dallas County, Tex.) and have been retained on a case in
21 Arizona related to gender identity and legal documentation of sex.

22 17. I am being compensated at an hourly rate for the actual time that I devote to
23 this case, at the rate of \$300 per hour for any review of records, preparation of reports, or
24 declarations. I will be compensated with a day rate of \$1920 for deposition and trial
25 testimony. My compensation does not depend on the outcome of this litigation, the
26 opinions that I express, or the testimony that I provide.

27
28

Medical and Scientific Background on Gender Identity and Gender Dysphoria

1
2 18. “Gender identity” is the medical term for a person’s internal, innate sense
3 of belonging to a particular sex. Everyone has a gender identity.

4 19. A person’s gender identity has a strong biological basis, although the
5 precise causal mechanism is not yet known. Research suggests that differences in
6 prenatal hormonal exposures, genetic factors, and brain structural differences may all
7 contribute.

8 20. The terms “gender role” and “gender identity” refer to different things.

9 21. Gender roles are behaviors, attitudes, and personality traits that a particular
10 society considers masculine or feminine, or associates with male or female social roles.
11 For example, the convention that girls wear pink and have longer hair, or that boys wear
12 blue and have shorter hair, are socially constructed gender roles from a particular culture
13 and historical period.

14 22. By contrast, gender identity does not refer to socially contingent behaviors,
15 attitudes, or personality traits. It is an internal and largely biological phenomenon.

16 23. A person’s gender identity is innate and cannot be changed by medical or
17 psychological intervention.

18 24. Living consistently with one’s gender identity is critical to the health and
19 well-being of any person, including transgender people.

20 25. Attempts to “cure” transgender individuals by forcing their gender identity
21 into alignment with their birth sex are harmful and ineffective. Those practices have been
22 denounced as unethical by all major professional associations of medical and mental
23 health professionals, such as the American Medical Association, the American Academy
24 of Pediatrics, the American Psychiatric Association, and the American Psychological
25 Association, among others.

26 26. From a medical perspective, a person’s sex is comprised of several
27 components, including, among others, internal reproductive organs, external genitalia,
28

1 chromosomes, hormones, gender identity, and secondary-sex characteristics. Diversity
2 and incongruence in these components of sex are a naturally occurring source of human
3 biological diversity.

4 27. When a child is born, a healthcare provider designates the child's sex as
5 male or female based on the child's observable anatomy. For most people, that initial
6 designation (often referred to as "assigned sex") turns out to be consistent with the
7 person's gender identity. For a transgender person, however, that initial designation turns
8 out to be inaccurate because it does not reflect the person's gender identity.

9 28. Due to the incongruence between their assigned sex and gender identity,
10 transgender people experience varying degrees of gender dysphoria, a serious medical
11 condition recognized in the American Psychiatric Association's *Diagnostic and*
12 *Statistical Manual of Mental Disorders* ("DSM-5") and the World Health Organization's
13 *International Classification of Diseases* ("ICD-10"), where it is referred to as "gender
14 incongruence." Gender dysphoria is highly treatable and can be effectively managed. If
15 left untreated, however, it can result in severe anxiety and depression, eating disorders,
16 substance abuse, self-harm, and suicidality.

17 29. When transgender adolescents are provided with appropriate medical
18 treatment and have parental and social support, they can thrive and grow into healthy
19 adults.

20 **The Medical Treatment of Gender Dysphoria in Adolescents**

21 30. The goal of medical treatment for transgender patients is to alleviate their
22 distress by allowing them to live consistently with their gender identity. Research and
23 clinical experience have consistently shown the medical treatments for gender dysphoria
24 to be safe and effective.

25 31. The prevailing standards of care for the treatment of gender dysphoria are
26 developed by WPATH. The WPATH Standards of Care represent expert consensus for
27 clinicians related to medical care for transgender people, based on the best science and
28

1 clinical experience. The WPATH Standards of Care were first published in 1979, more
2 than four decades ago, and have been continually updated to reflect new knowledge and
3 research. These standards have been endorsed by the major professional associations of
4 medical and mental health providers in the United States, including the American
5 Medical Association, the American Academy of Pediatrics, the American Psychiatric
6 Association, the American Psychological Association, and the Pediatric Endocrine
7 Society.

8 32. The Endocrine Society is a 100-year-old global membership organization
9 representing professionals in the field of adult and pediatric endocrinology. In 2017, the
10 Endocrine Society published clinical practice guidelines on treatment recommendations
11 for the medical management of gender dysphoria, in collaboration with the Pediatric
12 Endocrine Society, the European Societies for Endocrinology and Pediatric
13 Endocrinology, and WPATH, among others.

14 33. Together, the WPATH Standards of Care and the Endocrine Society's
15 clinical practice guidelines establish the prevailing standards governing the healthcare
16 and treatment of gender dysphoria in both youth and adults.

17 34. Undergoing treatment to alleviate gender dysphoria is commonly referred
18 to as transition. The transition process typically includes one or more of the following
19 three components: (i) social transition, including adopting a new name, pronouns,
20 appearance, and clothing, and correcting identity documents; (ii) medical transition,
21 including puberty-delaying medication and hormone-replacement therapy; and (iii) for
22 adults, surgeries to alter the appearance and functioning primary- and secondary-sex
23 characteristics. Surgery is rarely indicated for transgender minors.

24 35. At the onset of puberty, adolescents diagnosed with gender dysphoria may
25 be prescribed puberty-delaying medications to prevent the distress of developing physical
26 characteristics that conflict with the adolescent's gender identity. For example, a
27 transgender girl will experience no progression of physical changes caused by
28

1 testosterone, including male muscular development, facial and body hair, an Adam's
2 apple, or masculinized facial structures. And in a transgender boy, puberty-blocking
3 medication will prevent breast development, menstruation, and widening of the hips.

4 36. Thereafter, the treating provider may prescribe cross-sex hormones to
5 induce the puberty associated with the adolescent's gender identity. This treatment is
6 referred to as hormone therapy. The result of this treatment is that a transgender boy
7 typically has the same levels of circulating testosterone as other boys. Similarly, a
8 transgender girl who receives hormone therapy will typically have the same levels of
9 circulating estrogen and testosterone levels as other girls and significantly lower than
10 boys who have begun pubertal development.

11 **Sports and Gender**

12 37. Being transgender is not an accurate proxy for athletic performance or
13 ability. Sex chromosomes and genitals alone do not meaningfully affect athletic
14 performance.

15 38. Before puberty, there are no significant differences in athletic performance
16 between boys and girls. After puberty, boys perform better on average than girls in most
17 athletic competitions.

18 39. The biological driver of these average group differences is testosterone, not
19 anatomy or genetics. Both boys and girls produce testosterone. After puberty, however,
20 boys produce much higher levels of testosterone than girls, which results in increased
21 muscle mass and muscle strength. As a result, post-pubertal boys and men have an
22 athletic advantage over girls and women in many sports. *See, e.g.,* David J. Handelsman,
23 et al., *Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic*
24 *Performance*, 39 *Endocrine Revs.* 803–29 (2018).

25 40. Setting aside the narrow category of individuals with DSDs,¹ the ranges of
26

27 ¹ DSD includes a group of congenital conditions associated with atypical development of
28 internal and external genital structures. These conditions are caused by variations in genes,

1 testosterone in males and females do not overlap with each other.

2 41. There are transgender girls and women who have testosterone in the female
3 range because they are receiving hormone therapy or because, as a result of receiving
4 puberty-blocking medication, they never have gone through male puberty.

5 42. The fact that a girl is transgender, in itself, does not indicate that she has
6 any athletic advantage over other girls.

7 **Plaintiffs and Arizona's Ban on Transgender Girls in Sports**

8 43. There is no medical justification for Arizona to exclude Plaintiffs from
9 girls' interscholastic athletics because they are transgender.

10 44. Plaintiffs' attorneys have explained to me that Plaintiff Jane Doe is an 11-
11 year-old transgender girl who was diagnosed with gender dysphoria when she was about
12 seven years old and has lived her life as a girl since that time.

13 45. As part of her medical treatment for gender dysphoria, Jane's doctors have
14 determined that she has not yet started puberty. As a result, Jane has not experienced any
15 of the physiological changes that increased testosterone levels would cause in a pubescent
16 boy.

17 46. Plaintiffs' attorneys have explained to me that Plaintiff Megan Roe is a 15-
18 year-old transgender girl who was diagnosed with gender dysphoria when she was about
19 10 years old and has lived as a girl since that time.

20 47. As part of her medical treatment for gender dysphoria, Megan started to
21 receive puberty-blocking medication when she was 11 years old after clinical
22 documentation of the initial signs of puberty. This medication prevented her from
23 undergoing male puberty. Megan then started to receive hormone therapy when she was
24 12 years old. As a result, she has not experienced any of the physiological changes,
25 including muscle development, that increased testosterone levels would cause in a

26
27 development in utero, or hormones. Some women who have certain disorders of sexual
28 development may produce levels of testosterone that are typically seen only in men.

1 pubescent boy. Instead, the hormone therapy she has received has caused her to develop
2 many of the physiological changes associated with puberty in females.

3 48. SB 1165 suggests that biological “sex is determined at [fertilization] and
4 revealed at birth or . . . *in utero*.” S.B. 1165, 55th Leg., 2d Reg. Sess. (Ariz. 2022), § 2.

5 49. By suggesting sex to mean only biological sex determined at fertilization
6 and revealed in utero or at birth, Arizona prevents Plaintiffs from participating on girls’
7 teams because they are transgender girls. But the biological driver of average differences
8 in athletic performance between men and women is circulating testosterone—not a
9 person’s transgender status or their biological sex determined at fertilization and revealed
10 in utero or at birth. A person’s genetic makeup and anatomy at birth alone are not reliable
11 indicators of athletic performance.

12 50. Because both Jane and Megan have not experienced increased testosterone
13 levels that accompany male puberty, they do not have the biological characteristics that
14 would cause them to have an athletic advantage over other girls in some sports.

15 51. In addition, requiring Plaintiffs to participate on a boys’ team would
16 conflict with the standards of care for treating gender dysphoria in adolescents. Such a
17 requirement would be harmful to Plaintiffs’ mental, emotional, and physical health.

18 52. I declare under criminal penalty under the laws of Arizona that the
19 foregoing is true and correct.

20 Signed on the 4th day of April, 2023, in Ann Arbor, Michigan.

21 

22 Daniel Shumer, M.D.
23
24
25
26
27
28

EXHIBIT A

Daniel Shumer, MD MPH

Clinical Associate Professor in Pediatrics - Endocrinology

Email: dshumer@umich.edu

EDUCATION AND TRAINING

Education

- 08/2000-08/2003 BA, Northwestern University, Evanston, United States
- 08/2004-05/2008 MD, Northwestern University, Feinberg School of Medicine, Chicago, United States
- 07/2013-05/2015 MPH, Harvard T.H. Chan School of Public Health, Boston, United States

Postdoctoral Training

- 06/2008-06/2011 Residency, Pediatrics, Vermont Children's Hospital at Fletcher Allen Health Care, Burlington, VT
- 07/2011-06/2012 Chief Resident, Chief Resident, Vermont Children's Hospital at Fletcher Allen Health Care, Burlington, VT
- 07/2012-06/2015 Clinical Fellow, Pediatric Endocrinology, Boston Children's Hospital, Boston, MA

CERTIFICATION AND LICENSURE

Certification

- 10/2011-Present American Board of Pediatrics, General

Licensure

- Michigan, Medical License
- Michigan, Controlled Substance
- 08/2015-Present Michigan, Medical License

09/2015-Present Michigan, DEA Registration

09/2015-Present Michigan, Controlled Substance

WORK EXPERIENCE

Academic Appointment

10/2015-9/2022 Clinical Assistant Professor in Pediatrics - Endocrinology,
University of Michigan - Ann Arbor, Ann Arbor

09/2022-Present Clinical Associate Professor in Pediatrics - Endocrinology,
University of Michigan - Ann Arbor, Ann Arbor

Administrative Appointment

07/2019-Present Fellowship Director - Pediatric Endocrinology, Michigan
Medicine, Department of Pediatrics, Ann Arbor

07/2020-Present Medical Director of the University of Michigan
Comprehensive Gender Services Program, Michigan
Medicine, Ann Arbor

*Oversee the provision of care to transgender and gender non-
conforming patients at Michigan Medicine.*

07/2020-Present Education Lead - Pediatric Endocrinology, University of
Michigan - Department of Pediatrics, Ann Arbor

Clinical Appointments

04/2022-05/2023 Medical Director in UMMG Faculty Benefits Appt.,
University of Michigan - Ann Arbor, Ann Arbor

Private Practice

08/2013-09/2015 Staff Physician, Harvard Vanguard Medical Associates,
Braintree

RESEARCH INTERESTS

- Gender dysphoria
- Prader Willi Syndrome

CLINICAL INTERESTS

- Gender dysphoria
- Disorders of Sex Development
- Prader Willi Syndrome

GRANTS

Past Grants

A Phase 2b/3 study to evaluate the safety, tolerability, and effects of Livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome

PI

Millendo Therapeutics

04/2019 - 04/2021

HONORS AND AWARDS

National

2014 Annual Pediatric Endocrine Society Essay Competition:
Ethical Dilemmas in Pediatric Endocrinology: competition
winner - The Role of Assent in the Treatment of Transgender
Adolescents

Institutional

2012 - 2015 Harvard Pediatric Health Services Research Fellowship;
funded my final two years of pediatric endocrine fellowship
and provided tuition support for my public health degree

2016 The University of Michigan Distinguished Diversity Leaders Award, awarded by The Office of Diversity, Equity and Inclusion to the Child and Adolescent Gender Services Team under my leadership

2019 Lecturer of the Month, Department of Pediatrics, Michigan Medicine

TEACHING MENTORSHIP

Resident

07/2020-Present Rebecca Warwick, Michigan Medicine (co-author on publication #22)

Clinical Fellow

07/2017-06/2020 Adrian Araya, Michigan Medicine (co-author on publication #22, book chapter #4)

12/2020-Present Jessica Jary, Michigan Medicine - Division of Adolescent Medicine

Medical Student

09/2017-06/2020 Michael Ho, Michigan Medicine

07/2019-Present Hadrian Kinnear, University of Michigan Medical School (co-author on book chapter #3, abstract #3)

07/2019-Present Jourdin Batchelor, University of Michigan

TEACHING ACTIVITY

Regional

08/2018-Present Pediatric Boards Review Course sponsored by U-M: "Thyroid Disorders and Diabetes". Ann Arbor, MI

Institutional

- 12/2015-12/2015 Pediatric Grand Rounds: "Transgender Medicine - A Field in Transition". Michigan Medicine, Ann Arbor, MI
- 02/2016-02/2016 Medical Student Education: Panelist for M1 Class Session on LGBT Health, Doctoring Curriculum. Michigan Medicine, Ann Arbor, MI
- 02/2016-02/2016 Psychiatry Grand Rounds: "Transgender Medicine - A Field in Transition". Michigan Medicine, Ann Arbor, MI
- 03/2016-03/2017 Pharmacy School Education: "LGBT Health". University of Michigan School of Pharmacy, Ann Arbor, MI
- 04/2016-Present Course Director: Medical Student (M4) Elective in Transgender Medicine. Michigan Medicine, Ann Arbor, MI
- 04/2016-04/2016 Rheumatology Grand Rounds: "Gender Identity". Michigan Medicine, Ann Arbor, MI
- 05/2016-05/2016 Lecture to Pediatric Rheumatology Division: "Gender Dysphoria". Michigan Medicine, Ann Arbor, MI
- 07/2016-07/2016 Internal Medicine Resident Education: "Gender Identity". Michigan Medicine, Ann Arbor, MI
- 09/2016-09/2016 Presentation to ACU Leadership: "Gender Identity Cultural Competencies". Michigan Medicine, Ann Arbor, MI
- 10/2016-10/2016 Presentation to Department of Dermatology: "The iPledge Program and Transgender Patients". Michigan Medicine, Ann Arbor, MI
- 02/2017-02/2017 Swartz Rounds Presenter. Michigan Medicine, Ann Arbor, MI
- 02/2017-02/2017 Lecture to Division of General Medicine: "Transgender Health". Michigan Medicine, Ann Arbor, MI

- 02/2017-02/2017 Presentation at Collaborative Office Rounds: "Transgender Health". Michigan Medicine, Ann Arbor, MI
- 10/2017-10/2017 Family Medicine Annual Conference: "Transgender Medicine". Michigan Medicine, Ann Arbor, MI
- 12/2017-12/2017 Presenter at Nursing Unit 12-West Annual Educational Retreat: "Gender Identity at the Children's Hospital". Michigan Medicine, Ann Arbor, MI
- 02/2018-Present Pediatrics Residency Lecturer: "Puberty". Michigan Medicine, Ann Arbor, MI
- 02/2019-Present Medical Student (M1) Lecturer: "Pediatric Growth and Development". Michigan Medicine, Ann Arbor, MI
- 02/2019-Present Doctors of Tomorrow Preceptor: offering shadowing opportunities to students from Cass Technical High School in Detroit. Michigan Medicine, Ann Arbor, MI
- 03/2019-03/2019 Lecture to Division of Orthopedic Surgery: "Transgender Health". Michigan Medicine, Ann Arbor, MI

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

2012 - Present Pediatric Endocrine Society

COMMITTEE SERVICE

National

- 2014 - 2016 Pediatric Endocrine Society - Ethics Committee, Other, Member
- 2017 - present Pediatric Endocrine Society - Special Interest Group on Gender Identity, Other, Member
- 2018 - present Pediatric Endocrine Society - Program Directors Education Committee, Other, Member

Regional

2013 - 2015 Investigational Review Board - The Fenway Institute, Boston, MA, Other, Voting Member

Institutional

2017 - 2019 Department of Pediatrics at Michigan Medicine; Diversity, Equity, and Inclusion Committee, Other, Fellowship Lead

2017 - 2019 University of Michigan Transgender Research Group, Other, Director

VOLUNTEER SERVICE

2014 Camp Physician, Massachusetts, Served at a camp for youth with Type 1 Diabetes

SCHOLARLY ACTIVITIES

PRESENTATIONS

Extramural Invited Presentation Speaker

1. Grand Rounds, Shumer D, Loyola University School of Medicine, 07/2022, Chicago, Illinois

Other

1. Gender Identity, Groton School, 04/2015, Groton, MA

2. Television Appearance: Gender Identity in Youth, Channel 7 WXYZ Detroit, 04/2016, Southfield, MI

3. It Gets Better: Promoting Safe and Supportive Healthcare Environments for Sexual Minority and Gender Non-Conforming Youth, Adolescent Health Initiative: Conference on Adolescent Health, 05/2016, Ypsilanti, MI

4. Gender Identity, Humanists of Southeast Michigan, 09/2016, Farmington Hills, MI

5. Gender Identity, Pine Rest Christian Mental Health Services, 10/2016, Grand Rapids, MI
6. Pediatric Grand Rounds - Hormonal Management of Transgender Youth, Beaumont Children's Hospital, 11/2016, Royal Oak, MI
7. Transgender Youth: A Field in Transition, Temple Beth Emeth, 11/2016, Ann Arbor, MI
8. Transgender Youth: A Field in Transition, Washtenaw County Medical Society, 11/2016, Ann Arbor, MI
9. Pediatric Grand Rounds: Transgender Youth - A Field in Transition, St. John Hospital, 02/2017, Detroit, MI
10. Transgender Medicine, Veterans Administration - Ann Arbor Healthcare System, 05/2017, Ann Arbor, MI
11. Gender Identity, Hegira Programs, 05/2017, Detroit, MI
12. Care of the Transgender Adolescent, Partners in Pediatric Care, 06/2017, Traverse City, MI
13. Conference planner, host, and presenter: Transgender and Gender Non-Conforming Youth: Best Practices for Mental Health Clinicians, Educators, & School Staff; 200+ attendees from fields of mental health and education from across Michigan, Michigan Medicine, 10/2017, Ypsilanti, MI
14. Endocrinology Grand Rounds: Transgender Medicine, Wayne State University, 11/2017, Detroit, MI
15. Care of the Transgender Adolescent, St. John Hospital Conference: Transgender Patients: Providing Compassionate, Affirmative and Evidence Based Care, 11/2017, Grosse Pointe Farms, MI
16. Hormonal Care in Transgender Adolescents, Michigan State University School of Osteopathic Medicine, 11/2017, East Lansing, MI
17. Working with Transgender and Gender Non-Conforming Youth, Michigan Association of Osteopathic Family Physicians, 01/2018, Bellaire, MI

18. Community Conversations, Lake Orion, 01/2018, Lake Orion, MI
19. "I Am Jazz" Reading and Discussion, St. James Episcopal Church, 03/2019, Dexter, MI
20. Gender Identity, Michigan Organization on Adolescent Sexual Health, 10/2019, Brighton, MI; Port Huron, MI
21. Ask The Expert, Stand With Trans, 05/2020, Farmington Hills, MI (Virtual due to COVID)
22. Transgender Medicine, Michigan Association of Clinical Endocrinologists Annual Symposium, 10/2020, Grand Rapids, MI (Virtual due to COVID)
23. Transgender Youth in Primary Care, Michigan Child Care Collaborative (MC3), 10/2020, Ann Arbor, MI (Virtual due to COVID)
24. Lets Talk About Hormones, Stand With Trans, 10/2020, Farmington Hills, MI (Virtual due to COVID)
25. Gender Identity, Universalist Unitarian Church of East Liberty, 04/2021, Virtual due to COVID
26. Unconscious Bias, Ascension St. John Hospital, 05/2021, Virtual due to COVID

PUBLICATIONS/SCHOLARSHIP

Peer-Reviewed Articles

1. Vengalil N, Shumer D, Wang F: Developing an LGBT curriculum and evaluating its impact on dermatology residents, *Int J Dermatol*.61: 99-102, 01/2022. PM34416015

Chapters

1. Shumer: Coma. In Schwartz MW6, Lippincott Williams & Wilkins, Philadelphia, PA, (2012)
2. Shumer, Spack: Medical Treatment of the Adolescent Transgender Patient. In Đorđević M; Monstrey SJ; Salgado CJ Eds. CRC Press/Taylor & Francis, (2016)

3. Kinnear HA, **Shumer DE**: Duration of Pubertal Suppression and Initiation of Gender-Affirming Hormone Treatment in Youth. In FinlaysonElsevier, (2018)
4. Araya, **Shumer DE**: Endocrinology of Transgender Care – Children and Adolescents. In Poretsky; Hembree Ed. Springer, (2019)

Non-Peer Reviewed Articles

1. Shumer D: The Effect of Race and Gender Labels in the Induction of Traits, *Northwestern Journal of Race and Gender Criticism*.NA01/2014
2. Shumer D: A Tribute to Medical Stereotypes, *The Pharos, Journal of the Alpha Omega Alpha Medical Society*.Summer07/2017
3. Mohnach L, Mazzola S, Shumer D, Berman DR: Prenatal diagnosis of 17-hydroxylase/17,20-lyase deficiency (17OHD) in a case of 46,XY sex discordance and low maternal serum estriol, *Case Reports in Perinatal Medicine*.8(1)01/2018
4. Mohnach L, Mazzola S, Shumer D, Berman DR: Prenatal Diagnosis of 17-hydroxylase/17,20-lyase deficiency (17OHD) in a case of 46,XY sex discordance and low maternal serum estriol, *Case Reports in Perinatal Medicine*.8(1)12/2018
5. Kim C, Harrall KK, Glueck DH, **Shumer DE**, Dabelea D: Childhood adiposity and adolescent sex steroids in the EPOCH (Exploring Perinatal Outcomes among Children) study, *Clin Endocrinol (Oxf)*.91(4): 525-533, 01/2019. PM31278867
6. Araya A, Shumer D, Warwick R, Selkie E: 37. "I've Been Happily Dating For 5 Years" - Romantic and Sexual Health, Experience and Expectations in Transgender Youth, *Journal of Adolescent Health*.66(2): s20, 02/2020
7. Araya A, Shumer D, Warwick R, Selkie E: 73. "I think sex is different for everybody" - Sexual Experiences and Expectations in Transgender Youth, *Journal of Pediatric and Adolescent Gynecology*.33(2): 209-210, 04/2020
8. Araya AC, Warwick R, Shumer D, Selkie E, Rath T, Ibrahim M, Srinivasan A: Romantic Health in Transgender Adolescents, *Pediatrics*.Pediatrics01/2021
9. Martin S, Sandberg ES, **Shumer DE**: Criminalization of Gender-Affirming Care - Interfering with Essential Treatment for Transgender Children and

Adolescents, *New England Journal of Medicine*.385(7): 579-581, 08/2021.
PM34010528

Editorial Comment

1. **Shumer DE**, Harris LH, Opiari VP: The Effect of Lesbian, Gay, Bisexual, and Transgender-Related Legislation on Children, 01/2016. PM27575000
2. **Shumer DE**: Health Disparities Facing Transgender and Gender Nonconforming Youth Are Not Inevitable, 01/2018. PM29437859
3. Martin S, Sandberg ES, Shumer DE: Criminalization of Gender-Affirming Care - Interfering with Essential Treatment for Transgender Children and Adolescents, 01/2021

Erratum

1. Tishelman AC, Kaufman R, Edwards-Leeper L, Mandel FH, **Shumer DE**, Spack NP: Correction to Serving Transgender Youth: Challenges, Dilemmas, and Clinical Examples, [Professional Psychology: Research and Practice, 46(1), (2015) 37-45], *Professional Psychology: Research and Practice*.46(4): 249, 08/2015

Journal Articles

1. **Shumer DE**, Thaker V, Taylor GA, Wassner AJ: Severe hypercalcaemia due to subcutaneous fat necrosis: Presentation, management and complications, *Archives of Disease in Childhood: Fetal and Neonatal Edition*.99(5)01/2014. PM24907163
2. Tishelman AC, Kaufman R, Edwards-Leeper L, Mandel FH, **Shumer DE**, Spack NP: Serving transgender youth: Challenges, dilemmas, and clinical examples, *Professional Psychology: Research and Practice*.46(1): 37-45, 02/2015. PM26807001
3. Reisner SL, Veters R, Leclerc M, Zaslow S, Wolfrum S, **Shumer DE**, Mimiaga MJ: Mental health of transgender youth in care at an adolescent Urban community health center: A matched retrospective cohort study, *Journal of Adolescent Health*.56(3): 274-279, 03/2015. PM25577670

4. **Shumer DE**, Tishelman AC: The Role of Assent in the Treatment of Transgender Adolescents, *International Journal of Transgenderism*.16(2): 97-102, 04/2015. PM27175107
5. **Shumer DE**, Roberts AL, Reisner SL, Lyall K, Austin SB: Brief Report: Autistic Traits in Mothers and Children Associated with Child's Gender Nonconformity, *Journal of Autism and Developmental Disorders*.45(5): 1489-1494, 05/2015. PM25358249
6. Tishelman AC, Kaufman R, Edwards-Leeper L, Mandel FH, **Shumer DE**, Spack NP: Reply to comment on "serving transgender youth: Challenges, dilemmas, and clinical examples" by Tishelman et al. (2015), *Professional Psychology: Research and Practice*.46(4): 307, 08/2015. PM26858509
7. **Shumer DE**, Reisner SL, Edwards-Leeper L, Tishelman A: Evaluation of Asperger Syndrome in Youth Presenting to a Gender Dysphoria Clinic, *LGBT Health*.3(5): 387-390, 10/2016. PM26651183
8. Tishelman AC, **Shumer DE**, Nahata L: Disorders of sex development: Pediatric psychology and the genital exam, *Journal of Pediatric Psychology*.42(5): 530-543, 01/2017. PM27098964
9. Edwards-Leeper L, **Shumer DE**, Feldman HA, Lash BR, Tishelman AC: Psychological profile of the first sample of transgender youth presenting for medical intervention in a U.S. pediatric gender center, *Psychology of Sexual Orientation and Gender Diversity*.4(3): 374-382, 01/2017
10. **Shumer DE**, Abrha A, Feldman HA, Carswell J: Overrepresentation of adopted adolescents at a hospital-based gender dysphoria clinic, *Transgender Health*.2(1): 76-79, 07/2017. PM28861549
11. Strang JF, Meagher H, Kenworthy L, de Vries AL C, Menvielle E, Leibowitz S, Janssen A, Cohen-Kettenis P, **Shumer DE**, Edwards-Leeper L, Pleak RR, Spack N, Karasic DH, Schreier H, Balleur A, Tishelman A, Ehrensaft D, Rodnan L, Kushner ES, Mandel F, Caretto A, Lewis HC, Anthony LG: Initial Clinical Guidelines for Co-Occurring Autism Spectrum Disorder and Gender Dysphoria or Incongruence in Adolescents, *Journal of Clinical Child and Adolescent Psychology*.47(1): 105-115, 01/2018. PM27775428

12. Selkie E, Adkins V, Masters E, Bajpai A, **Shumer DE**: Transgender Adolescents' Uses of Social Media for Social Support, *Journal of Adolescent Health*.66(3): 275-280, 03/2020. PM31690534
13. Warwick RM, **Shumer DE**: Gender-affirming multidisciplinary care for transgender and non-binary children and adolescents, *Children's Health Care*.01/2021
14. Araya AC, Warwick R, **Shumer DE**, Selkie E: Romantic relationships in transgender adolescents: A qualitative study, *Pediatrics*.147(2)02/2021. PM33468600
15. Warwick RM, Araya AC, **Shumer DE**, Selkie EM: Transgender Youths' Sexual Health and Education: A Qualitative Analysis, *Journal of Pediatric and Adolescent Gynecology*.35(2): 138-146, 04/2022. PM34619356

Letters

1. Strang JF, Janssen A, Tishelman A, Leibowitz SF, Kenworthy L, McGuire JK, Edwards-Leeper L, Mazefsky CA, Rofey D, Bascom J, Caplan R, Gomez-Lobo V, Berg D, Zaks Z, Wallace GL, Wimms H, Pine-Twaddell E, **Shumer DE**, Register-Brown K, Sadikova E, Anthony LG: Revisiting the Link: Evidence of the Rates of Autism in Studies of Gender Diverse Individuals, *Journal of the American Academy of Child and Adolescent Psychiatry*.57(11): 885-887, 11/2018. PM30392631

Letters to editor

1. **Shumer DE**: Doctor as environmental steward, 01/2009. PM19364173

Notes

1. **Shumer DE**, Mehringer J, Braverman L, Dauber A: Acquired hypothyroidism in an infant related to excessive maternal iodine intake: Food for thought, *Endocrine Practice*.19(4): 729-731, 07/2013. PM23512394

Podcasts

1. Gaggino L, Shumer WG D: Pediatric Meltdown: Caring for Transgender Youth with Compassion: What Pediatricians Must Know, 01/2020

Reviews

1. **Shumer DE**, Spack NP: Current management of gender identity disorder in childhood and adolescence: Guidelines, barriers and areas of controversy, *Current Opinion in Endocrinology, Diabetes and Obesity*.20(1): 69-73, 02/2013. PM23221495
2. Guss C, **Shumer DE**, Katz-Wise SL: Transgender and gender nonconforming adolescent care: Psychosocial and medical considerations, *Current Opinion in Pediatrics*.27(4): 421-426, 08/2015. PM26087416
3. **Shumer DE**, Nokoff NJ, Spack NP: Advances in the Care of Transgender Children and Adolescents, *Advances in Pediatrics*.63(1): 79-102, 08/2016. PM27426896

Short Surveys

1. **Shumer DE**, Spack NP: Transgender medicine-long-term outcomes from 'the Dutch model', *Nature Reviews Urology*.12(1): 12-13, 01/2015. PM25403246

Abstracts/Posters

1. Shumer D, Kinnear H, McLain K, Morgan H: Development of a Transgender Medicine Elective for 4th Year Medical Students, National Transgender Health Summit, Oakland, CA, 2017
2. Shumer D: Overrepresentation of Adopted Children in a Hospital Based Gender Program, World Professional Association of Transgender Health Biennial International Symposium, Amsterdam, The Netherlands, 2016
3. Shumer D: Mental Health Presentation of Transgender Youth Seeking Medical Intervention, World Professional Association of Transgender Health Biennial International Symposium, Amsterdam, The Netherlands, 2016
4. Adkins V, Masters E, Shumer D, Selkie E: Exploring Transgender Adolescents' Use of Social Media for Support and Health Information Seeking (Poster Presentation), Pediatric Research Symposium, Ann Arbor, MI, 2017